GTC Biotherapeutics (fka GTCB)

[DewDiligence]

FoB or brand?

You’re quite right, Vinnie: a drug can’t be both similar and substantially better at the same time.

If GTC’s enhanced ADCC to turns out to be something of great consequence, the drugs that have it will have to be commercialized as brands.

If GTC’s enhanced ADCC turns out to be much ado about nothing, the drugs that have it may be suitable for commercialization as FoB’s.

In the vast middle ground—where enhanced ADCC has some clinical value but not a lot—GTC will have to decide whether it makes more sense to bring a drug to market as a brand or an FoB. GTC’s CD20 program may fit into this third category.